

# Vaccine Combinations - Primary Series

caa 30/05/24

**Legend:**  
 V = Pfizer(>=6mo) or Moderna(>=6mo) or Novavax(>=12yo) ; as applicable for age  
 S = Sinovac (>=18yo or 3-17yo MI to V)  
 O = non-PSAR WHO EUL vaccine (excluding Sinopharm)  
 No. of days is recommended interval from last dose & age eligibility applies

MI = medically ineligible  
 - = part of primary series  
 + = part of booster series

	Vaccinations received	Vaccination for Primary Series <sup>1</sup> & †	Completed permutation
<b>NON-IMMUNOCOMPROMISED</b>	V	1 dose of V (56 days) <b>OR</b> 1 dose of S (56 days) [not preferred]	V-V / V-S
	S	1 dose of V (56 days) <b>OR</b> 1 dose of S (56 days) [not preferred]	S-V / S-S
	O# (pls see footnote)	1 dose of V (56 days) <b>OR</b> 1 dose of S (56 days) [not preferred]	O-V / O-S
	V-V	NIL	V-V
	S-S / V-S / S-V	NIL	S-S / V-S / S-V
	S-S-S / S-S-V / S-V-S / S-V-V / V-S-S / V-S-V	NIL	S-S-S / S-S-V / S-V-S / S-V-V / V-S-S / V-S-V
	P-P-P <sup>2</sup> / P-P-S <sup>2</sup> (Infant who received previous 3-dose Primary Series with P and S)	NIL	P-P-P <sup>2</sup> / P-P-S <sup>2</sup>
	O-O / O-V / V-O / O-S / S-O	NIL	O-O / O-V / V-O / O-S / S-O
O-S-V / S-O-V / O-S-S / S-O-S	NIL	O-S-V / S-O-V / O-S-S / S-O-S	

<sup>1</sup> EC19V recommends that individuals who have not been vaccinated against COVID-19 receive two initial vaccine doses at an interval of 56 days apart

<sup>2</sup> Infants 6mth to < 5yo are recommended to complete their Primary Series. Currently Moderna(2 doses), Pfizer(2 doses instead of previous 3 doses) and Sinovac(2 doses instead of previous 3 doses; for ≥ 3yo MI to mRNA vaccines) vaccines are used for Infant Primary Series. Other Covid-19 vaccines, if given locally, will be considered as invalid, If in doubt, please check with VOTG HQ.

# A single dose of Janssen (Ad26.COV2.S) or CanSinoBIO(Convidecia) vaccine is considered O-O and hence no further doses are needed to complete the Primary Series.

\* Recovered persons who were unvaccinated, or partially vaccinated before their infection, can proceed to complete the standard primary vaccination series. They are recommended to receive remaining vaccine doses from 3 months or more after the date of infection to reduce their risk of reinfection. Recovered persons who are recommended or encouraged to receive an additional COVID-19 vaccine dose after their last vaccine dose should do so at the recommended interval thereafter, and at least 28 days after the infection although an interval of three months from the infection is recommended for better effectiveness.

# Vaccine Combinations – Additional Dose

caa 30/05/24

### Legend:

V = Pfizer(>= 6mo) or Moderna(>=6mo) or Novavax(>=12yo) : as applicable for age  
 S = Sinovac (>=18yo or 3-17yo MI to V)  
 O = non-PSAR WHO EUL vaccine (excluding Sinopharm)  
 B1 = 1st Booster  
 No. of days is recommended interval from last dose & age eligibility applies

MI = medically ineligible  
 - = part of primary series  
 + = part of booster series

	Primary Series or with any booster / additional dose received	Vaccination for 2024 Additional Dose <sup>1</sup> & †	Completed permutation
NON-IMMUNOCOMPROMISED	Primary Series <sup>2</sup> Primary Series + B1 <sup>3</sup> Primary Series + B1 <sup>3</sup> + ...	1 dose of V (365 days) OR 1 dose of S (365 days) [not preferred]	Primary Series + V Primary Series + S Primary Series + B1 + V Primary Series + B1 + S Primary Series + B1 + ... + V Primary Series + B1 + ... + S

RESTRICTED

<sup>1</sup> The EC19V has updated its recommendations to advise individuals to receive an additional dose in 2024, around one year (no earlier than five months) after the last dose. The additional dose is :

- a. Recommended for all persons aged 60 years and above, medically vulnerable individuals and residents of aged care facilities
- b. Encouraged for all individuals aged 6 months and above, especially healthcare workers as well as household members and caregivers of medically vulnerable individuals

<sup>2</sup> Infants 6mth to < 5yo are recommended to complete their Primary Series. Currently Moderna(2 doses), Pfizer(2 doses instead of previous 3 doses) and Sinovac(2 doses instead of previous 3 doses; for ≥ 3yo MI to mRNA vaccines) vaccines are used for Infant Primary Series. Other Covid-19 vaccines, if given locally, will be considered as invalid, if in doubt, please check with VOTG HQ.

<sup>3</sup> Primary Series with any Booster(for >=5yo) may include O as part of vaccine permutation with prevailing interval criteria e.g. O-O+V, O-O+O, O-V+V, V-V+O+V, V-O+O+O, O\*+V+O(where O\* is Janssen or CanSinoBIO)

\* Recovered persons who were unvaccinated, or partially vaccinated before their infection, can proceed to complete the standard primary vaccination series. They are recommended to receive remaining vaccine doses from 3 months or more after the date of infection to reduce their risk of reinfection. Recovered persons who are recommended or encouraged to receive an additional COVID-19 vaccine dose after their last vaccine dose should do so at the recommended interval thereafter, and at least 28 days after the infection although an interval of three months from the infection is recommended for better effectiveness.

# Vaccine Combinations – Primary Series (Immunocompromised)

caa 30/05/24

## Legend:

V = Pfizer(>=6yo) or Moderna(>=6mo) or Novavax(>=12yo) ; as applicable for age)

S = Sinovac (Only >= 3yo MI to V)

O = non-PSAR WHO EUL vaccine (excluding Sinopharm)

No. of days is recommended interval from last dose & age eligibility applies

MI = medically ineligible

- = part of primary series

+ = part of booster series

Immunocompromised persons should complete their Primary Series with mRNA vaccines, as per immunocompetent persons. They are then recommended to receive a 3<sup>rd</sup> initial dose as part of Enhanced Primary Series :

	Vaccinations received <sup>1</sup>	Vaccination for Enhanced Primary Series	Completed permutation
IMMUNOCOMPROMISED	V-V	Enhanced Primary series <sup>3 &amp; †</sup> with : 1 dose of V (60 days)	V-V-(V)
	S-S-S / S-S-V / S-V-S / S-V-V / V-S-S / V-S-V  P-P-P <sup>2</sup> / P-P-S <sup>2</sup> (Infant who received previous 3-dose Primary Series with P and S)	NIL (no recommendation)	S-S-S / S-S-V / S-V-S / S-V-V / V-S-S / V-S-V  P-P-P / P-P-S
	O# / O-O / O-V V-O / S-O / O-S	Further doses are physician-directed and will be reviewed on a case-by-case basis.	

<sup>1</sup> EC19V recommends that individuals who have not been vaccinated against COVID-19 receive two initial vaccine doses at an interval of 56 days apart

<sup>2</sup> Infants 6mth to < 5yo are recommended to complete their Primary Series. Currently Moderna(2 doses), Pfizer(2 doses instead of previous 3 doses) and Sinovac(2 doses instead of previous 3 doses; for ≥ 3yo MI to mRNA vaccines) vaccines are used for Infant Primary Series. Other Covid-19 vaccines, if given locally, will be considered as invalid, If in doubt, please check with VOTG HQ.

<sup>3</sup> Immunocompromised person may be vaccinated in the hospital setting or at community vaccination centre setting with a memo provided by treating specialist. The 3<sup>rd</sup> initial dose in the Enhanced Primary Series (denoted in brackets above) should be given 60 days after the last dose of V-V and should be the same V vaccine as the doses in V-V.

# A single dose of Janssen (Ad26.COVS.2.S) or CanSinoBIO(Convidecia) vaccine is considered O-O and hence no further doses are needed to complete the Primary Series.

\* Recovered persons who were unvaccinated, or partially vaccinated before their infection, can proceed to complete the standard primary vaccination series. They are recommended to receive remaining vaccine doses from 3 months or more after the date of infection to reduce their risk of reinfection. Recovered persons who are recommended or encouraged to receive an additional COVID-19 vaccine dose after their last vaccine dose should do so at the recommended interval thereafter, and at least 28 days after the infection although an interval of three months from the infection is recommended for better effectiveness.

# Vaccine Combinations – Additional Dose (Immunocompromised)

caa 30/05/24

## Legend:

V = Pfizer(>=6mo) or Moderna(>=6mo) or Novavax(>=12yo); as applicable for age)

S = Sinovac (>=18yo or 3-17yo MI to V)

O = non-PSAR WHO EUL vaccine (excluding Sinopharm)

B1 = 1st Booster

No. of days is recommended interval from last dose & age eligibility applies

MI = medically ineligible

- = part of primary series

+ = part of booster series

	Primary Series or with any booster / additional dose received	Vaccination for 2024 Additional Dose <sup>1</sup> & †	Completed permutation
<b>IMMUNOCOMPROMISED</b>	Primary Series <sup>2</sup> Primary Series + B1 <sup>3</sup> Primary Series + B1 <sup>3</sup> + ... Enhanced Primary Series Enhanced Primary Series + B1 <sup>3</sup> Enhanced Primary Series + B1 <sup>3</sup> + ...	<b>1 dose of V<sup>4</sup> (365 days)</b>  <b>OR</b>  <b>1 dose of S<sup>4</sup> (365 days)</b> [not preferred]	Primary Series + V Primary Series + S Primary Series + B1 + V Primary Series + B1 + S Primary Series + B1 + ... + V Primary Series + B1 + ... + S Enhanced Primary Series + V Enhanced Primary Series + S Enhanced Primary Series + B1 + V Enhanced Primary Series + B1 + S Enhanced Primary Series + B1 + ... + V Enhanced Primary Series + B1 + ... + S

RESTRICTED

<sup>1</sup> The EC19V has updated its recommendations to advise individuals to receive an additional dose in 2024, around one year (no earlier than five months) after the last dose. The additional dose is :

- a. Recommended for all persons aged 60 years and above, medically vulnerable individuals and residents of aged care facilities
- b. Encouraged for all individuals aged 6 months and above, especially healthcare workers as well as household members and caregivers of medically vulnerable individuals

<sup>2</sup> Infants 6mth to < 5yo are recommended to complete their Primary Series. Currently Moderna(2 doses), Pfizer(2 doses instead of previous 3 doses) and Sinovac(2 doses instead of previous 3 doses; for ≥ 3yo MI to mRNA vaccines) vaccines are used for Infant Primary Series. Other Covid-19 vaccines, if given locally, will be considered as invalid, If in doubt, please check with VOTG HQ.

<sup>3</sup> Primary Series with any Booster(for >=5yo) may include O as part of Vaccine permutation with prevailing interval criteria e.g. O-O+V, O-O+O, O-V+V, V-V+O+V, V-O+O+O, O\*+V+O(where O\* is Janssen or CanSinoBIO)

<sup>4</sup> Immunocompromised person may be vaccinated in the hospital setting or at community vaccination centre setting with a memo provided by treating specialist. Immunocompromised persons can be considered to receive the additional dose of COVID-19 vaccine earlier, from 5 months after their last dose in consultation with their treating physician for better protection.

\* Recovered persons who were unvaccinated, or partially vaccinated before their infection, can proceed to complete the standard primary vaccination series. They are recommended to receive remaining vaccine doses from 3 months or more after the date of infection to reduce their risk of reinfection. Recovered persons who are recommended or encouraged to receive an additional COVID-19 vaccine dose after their last vaccine dose should do so at the recommended interval thereafter, and at least 28 days after the infection although an interval of three months from the infection is recommended for better effectiveness.

# Vaccination Requirements for Completion of COVID-19 Vaccine Course

caa 30/05/2024

Manufacturer	Name of Vaccine	Doses for Primary Vaccination	Recommended and minimum interval between doses <For NVP we shall follow the recommended>	Minimum Interval between doses [For vaccination to be valid]
Moderna	mRNA-1273	2 doses	56 (28) days	24 days
Astrazeneca	AZD1222-Vaxzeveria (ChAdOx1_nCoV-19)	2 doses	56 (28) days	24 days
Serum Institute of India	Covishield (ChAdOx1_nCoV-19)	2 doses		
Janssen	Ad26.COV2.S	1 dose	-	NA
Pfizer/BioNTech	BNT162b2/COMIRNATY Tozinameran (INN)	2 doses	56 (21) days	17 days
Pfizer/BioNTech (for ages 6mo-4 yrs)	BNT162b2/COMIRNATY (3mcg, for ages 6mo-4 yrs) Tozinameran (INN)	2 doses	56 (21) days	17 days
Sinopharm	SARS-CoV-2 Vaccine (VeroCell), Inactivated (InCoV)	2 doses	Interval between D1 and D2: 56 (21) days	Interval between Dose 1 and Dose 2: 17 days
Sinovac	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™	2 doses	Interval between D1 and D2: 56 (28) days	Interval between Dose 1 and Dose 2: 13 days
Covaxin	Bharat Biotech BBV152 COVAXIN®	2 doses	56 (28) days	24 days
Novavax	NVX-CoV2373/Covovax/Nuvaxovid	2 doses	56 (21) days	17 days
CanSinoBIO	Convidecia	1 dose	-	NA
Heterologous vaccine regimens in COVID-19 naïve persons	Following WHO EUL vaccine: <ul style="list-style-type: none"> <li>• BNT162b2/COMIRNATY Tozinameran (INN)</li> <li>• mRNA-1273</li> <li>• AZD1222-Vaxzeveria (ChAdOx1_nCoV-19)</li> <li>• Covishield (ChAdOx1_nCoV-19)</li> <li>• Covaxin/Bharat</li> <li>• NVX-CoV2373/Covovax/Nuvaxovid</li> <li>• SARS-CoV-2 Vaccine (VeroCell), Inactivated (InCoV)</li> <li>• COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™</li> </ul>	2 doses	56 (21) days	17 days